EN-US Thu, 23 May 2013 11:37:13 -0400 243197 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/geoI10cuJNs/viropharma-reports-loss-in-1q-analyst-blog-cm243197 Investing Business Stocks ViroPharma Inc.'s  ( VPHM ) first quarter 2013 adjusted loss (excluding special items but including stock-based compensation) came in at 7 cents per share compared to year-ago earnings<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/geoI10cuJNs" height="1" width="1"/> Thu, 02 May 2013 21:53:09 Z 2013-05-02T18:32:26Z Zacks Equity Research HALO ONXX UCBJF VPHM http://www.nasdaq.com/article/viropharma-reports-loss-in-1q-analyst-blog-cm243197 242785 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DEAYpbTebQQ/optimers-dificid-cleared-down-under-analyst-blog-cm242785 Investing Business Stocks Optimer Pharmaceuticals ( OPTR ) received encouraging news recently when the Australian regulatory body (Australian Therapeutic Goods Administration) cleared its drug Dificid (fidaxomicin).<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/DEAYpbTebQQ" height="1" width="1"/> Thu, 02 May 2013 02:28:01 Z 2013-05-01T23:50:52Z Zacks Equity Research ALPMY CDI INCY OPTR VPHM http://www.nasdaq.com/article/optimers-dificid-cleared-down-under-analyst-blog-cm242785 239822 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1pk1krOJEUU/pipeline-progresses-at-viropharma-analyst-blog-cm239822 Investing Business Stocks ViroPharma Incorporated ( VPHM ) recently announced results from a phase II study of its candidate VP20621 (non-toxigenic Clostridium difficile), which is being developed to prevent<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/1pk1krOJEUU" height="1" width="1"/> Wed, 24 Apr 2013 02:11:00 Z 2013-04-24T14:19:55Z Zacks Equity Research ALNY CDI HAE UCBJF VPHM http://www.nasdaq.com/article/pipeline-progresses-at-viropharma-analyst-blog-cm239822 222238 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gFYCiiSj8a8/viropharma-tops-on-all-fronts-analyst-blog-cm222238 Investing Business Stocks ViroPharma Inc.'s ( VPHM ) fourth quarter 2012 adjusted earnings (including stock-based compensation) of 3 cents per share were above the Zacks Consensus Estimate of a penny but<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/gFYCiiSj8a8" height="1" width="1"/> Fri, 01 Mar 2013 02:38:01 Z 2013-02-28T23:33:28Z Zacks Equity Research AVNR BAYRY HALO VPHM http://www.nasdaq.com/article/viropharma-tops-on-all-fronts-analyst-blog-cm222238 208954 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DMCR9hhQZxg/data-on-viropharmas-cinryze-analyst-blog-cm208954 Investing Business Stocks ViroPharma ( VPHM ) recently announced that The Journal of Pediatrics published data in an article on Jan 14, 2013, which demonstrated that key product Cinryze (C1 esterase inhibitor<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/DMCR9hhQZxg" height="1" width="1"/> Sat, 19 Jan 2013 04:13:52 Z 2013-01-19T00:15:00Z Zacks Equity Research HAE VPHM VRX http://www.nasdaq.com/article/data-on-viropharmas-cinryze-analyst-blog-cm208954 207620 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-LDHr4og8eQ/one-biotech-stock-investors-are-unfairly-ignoring-cm207620 Investing Investing Ideas Shares of biotech company Halozyme Therapeutics (NASDAQ: HALO ) were unchanged in pre-market trading on Tuesday following Monday's gain of more than 15 percent. Investors bid up the stock<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/-LDHr4og8eQ" height="1" width="1"/> Tue, 15 Jan 2013 19:00:00 Z 2013-01-16T15:39:19Z Tim Parker BAX DNDN GILD HALO VPHM http://www.nasdaq.com/article/one-biotech-stock-investors-are-unfairly-ignoring-cm207620 205363 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CnolaPxkC0g/upbeat-2013-from-viropharma-analyst-blog-cm205363 Investing Business Stocks ViroPharma Incorporated ( VPHM ) recently provided guidance for 2013. ViroPharma expects net product sales between $450 million and $475 million in 2013 on a worldwide basis.<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/CnolaPxkC0g" height="1" width="1"/> Wed, 09 Jan 2013 03:29:01 Z 2013-01-09T00:04:55Z Zacks Equity Research HALO IRWD VPHM VRX http://www.nasdaq.com/article/upbeat-2013-from-viropharma-analyst-blog-cm205363 201934 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xSMe-4X7Yfs/mdco-scores-in-solo1-trial-analyst-blog-cm201934 Investing Business Stocks The Medicines Company ( MDCO ) recently received good news with the company announcing positive results on its phase III antibiotic candidate, oritavancin. Oritavancin was being evaluated<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/xSMe-4X7Yfs" height="1" width="1"/> Mon, 24 Dec 2012 21:40:01 Z 2012-12-24T18:42:32Z Zacks Equity Research GAIN MDCO SPA TRGT VPHM http://www.nasdaq.com/article/mdco-scores-in-solo1-trial-analyst-blog-cm201934 189928 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vaE0qzkIZgo/viropharma-presents-cinryze-data-analyst-blog-cm189928 Investing Business Stocks ViroPharma Inc. ( VPHM ) presented promising data on Cinryze at the American College of Allergy, Asthma and Immunology's (ACAAI) annual congress. Data was presented from a post marketing<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/vaE0qzkIZgo" height="1" width="1"/> Thu, 15 Nov 2012 01:00:01 Z 2012-11-14T21:25:08Z Zacks Equity Research HAE HALO VPHM http://www.nasdaq.com/article/viropharma-presents-cinryze-data-analyst-blog-cm189928 186478 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4Yt_eQfmo0g/watson-beats-revises-outlook-analyst-blog-cm186478 Investing Business Stocks Watson Pharmaceuticals Inc. 's ( WPI ) third quarter 2012 earnings (excluding special items) of $1.35 per share surpassed the Zacks Consensus Estimate by 6 cents. Earnings increased 23.9%<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/4Yt_eQfmo0g" height="1" width="1"/> Fri, 02 Nov 2012 00:26:52 Z 2012-11-01T21:31:41Z Zacks Equity Research SNY VPHM WPI http://www.nasdaq.com/article/watson-beats-revises-outlook-analyst-blog-cm186478 185361 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/C3LTDStvsOg/revenues-fall-at-viropharma-analyst-blog-cm185361 Investing Business Stocks ViroPharma Inc.'s ( VPHM ) third quarter 2012 adjusted earnings (including stock based compensation) of 3 cents per share were slightly above the Zacks Consensus Estimate of 2 cents but<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/C3LTDStvsOg" height="1" width="1"/> Mon, 29 Oct 2012 22:27:00 Z 2012-10-29T19:29:51Z Zacks Equity Research HALO ILNS VPHM http://www.nasdaq.com/article/revenues-fall-at-viropharma-analyst-blog-cm185361 176460 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Y77kBfA1iUs/pertaining-to-relief-for-viropharma-analyst-blog-cm176460 Investing Business Stocks The US Food and Drug Administration (FDA) recently informed ViroPharma Incorporated ( VPHM ) that the company may continue with its clinical studies of the subcutaneous administration of<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/Y77kBfA1iUs" height="1" width="1"/> Tue, 25 Sep 2012 23:36:01 Z 2012-09-25T20:40:18Z Zacks Equity Research HALO VPHM http://www.nasdaq.com/article/pertaining-to-relief-for-viropharma-analyst-blog-cm176460 163369 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pByNZmdKYkc/premarket-most-active-for-aug-13-2012-siri-amkr-fnp-dhi-hst-tc-len-cdns-lxp-vrsn-cien-vphm-cm163369 News Headlines Pre-market Most Active The NASDAQ 100 Pre-Market Indicator is up 4.24 to 2,727.2. The total Pre-Market volume is currently 21,735,073 shares traded. The following are the most active stocks for the pre-market<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/pByNZmdKYkc" height="1" width="1"/> Mon, 13 Aug 2012 16:36:08 Z 2012-08-13T13:01:25Z NASDAQ.com News AMKR CDNS CIEN DHI FNP HST LEN LXP SIRI TC VPHM VRSN http://www.nasdaq.com/article/premarket-most-active-for-aug-13-2012-siri-amkr-fnp-dhi-hst-tc-len-cdns-lxp-vrsn-cien-vphm-cm163369 162959 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZjPA_WxpfhA/viropharma-misses-zacks-estimates-analyst-blog-cm162959 Investing Business Stocks ViroPharma Inc.'s ( VPHM ) second quarter 2012 adjusted earnings of 2 cents per share was well short of the Zacks Consensus Estimate of 10 cents and the year-ago earnings of 38 cents. The<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/ZjPA_WxpfhA" height="1" width="1"/> Fri, 10 Aug 2012 17:14:01 Z 2012-08-10T14:25:46Z Zacks Equity Research HALO VPHM http://www.nasdaq.com/article/viropharma-misses-zacks-estimates-analyst-blog-cm162959 162087 http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2w3nCQyYuMg/vphm-manufacturing-process-approved-analyst-blog-cm162087 Investing Business Stocks The US Food and Drug Administration (FDA) recently approved ViroPharma Incorporated 's ( VPHM ) supplement to the Cinryze Biologics License Application (BLA) for industrial scale<img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/2w3nCQyYuMg" height="1" width="1"/> Wed, 08 Aug 2012 03:17:01 Z 2012-08-08T00:22:12Z Zacks Equity Research CRL HAE HALO VPHM http://www.nasdaq.com/article/vphm-manufacturing-process-approved-analyst-blog-cm162087